Ormeval provides decision-support intelligence derived from public sources. It is not investment, medical, legal or regulatory advice, and states nothing about the value of any security. Forward figures are deterministic model estimates, not guidance.
Missing row, now added. Label 1.16: 'in combination with axitinib, for the first-line treatment of adult patients with advanced RCC.' No PD-L1 requirement - patients in KEYNOTE-426 (NCT02853331) were enrolled regardless of PD-L1 tumor expression status, and the label carries no biomarker gate for this combination. Distinct from two other RCC entries on this asset: the adjuvant, post-nephrectomy indication built on KEYNOTE-564, and Bavencio's separate avelumab+axitinib 1L RCC combination (JAVELIN Renal 101, a competitor asset, not this one).
Baseline profile - No forecast model has been built for this indication yet. What is shown is the approval and trial record, with its sources.
These are regulatory approval dates for this indication (FDA, EMA, PMDA, NMPA), not commercial launch; pricing and reimbursement follow. Cross-checked against Merck & Co. disclosures and regulator databases.
Synthesised from this indication's verified milestones (pivotal readout, regulatory approvals/decisions) and the asset's expected LOE: filled = passed, open = upcoming. Competitor-level catalysts are tracked on the disease-landscape view below.
Revenue & outlook: KeytrudaAsset-level chart: indication funnel not yet modelled
Open editable forecast for this indication →Solid line = reported revenue; dashed line and band = Ormeval's modelled outlook from the current year.
Asset-level reported revenue and cited outlook (all indications). The per-indication contribution is a model estimate. Open the editable forecast funnel to shape it by indication and region.
What it shows. This indication's forecast funnel is not yet modelled, so the chart shows the whole asset's reported revenue and cited outlook across all its indications.
What to look for. The asset's overall size and trajectory as context; the editable forecast lets you carve out this indication's share by region.
Common misread. This is the asset total, not this indication alone; the per-indication contribution is a model estimate until the funnel is built.
| Asset | Company | Trajectory | Latest quarter | FY latest | US LOE | Approved | Pipeline (Ph I · II · III · filed) |
|---|---|---|---|---|---|---|---|
| Opdivo | Bristol Myers Squibb | $2.48BQ2 26 | $10.0BFY 25 | 2028 | 23 | 0 · 0 · 3 · 0 | |
| Imfinzi | AstraZeneca | $1.85BQ2 26 | $6.06BFY 25 | ~2031 | 11 | 0 · 8 · 11 · 0 | |
| Tecentriq | Roche | $1.07BQ2 26 | $4.28BFY 25 | 2030 | 9 | 0 · 0 · 2 · 1 | |
| Libtayo | Regeneron | $438MQ1 26 | $1.45BFY 25 | 2035 | 5 | 0 · 8 · 3 · 0 |
1 Product revenue as recorded by the company in the Company column, for scale within Keytruda's tracked competitive set, not the total market. 2 In USD at a fixed reference rate; % reported in the reporting currency. 3 As of Q2 2026 reported figures.
What it shows. The asset's curated competitive set, shown here because this indication does not yet have its own modelled landscape.
What to look for. Which rivals are at the same line of therapy and whose next readout or approval could shift share in this setting.
Common misread. This is the asset-wide rival set, not filtered to this exact indication; the modelled indications carry the setting-specific head-to-head.
Reported figures are public facts from company filings; the forward peak is Ormeval's own modelled estimate, not company guidance and not analyst consensus. Approval and readout dates are cross-checked against public regulator and company disclosures. Not investment advice.